![Sebastian Amigorena](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Sebastian Amigorena
Corporate Officer/Principal presso Mnemo Therapeutics SAS
Profilo
Sebastian Amigorena is currently working as the Senior Vice President-Immunology at Mnemo Therapeutics SAS.
Posizioni attive di Sebastian Amigorena
Società | Posizione | Inizio |
---|---|---|
Mnemo Therapeutics SAS
![]() Mnemo Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022. | Corporate Officer/Principal | - |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
Mnemo Therapeutics SAS
![]() Mnemo Therapeutics SAS Miscellaneous Commercial ServicesCommercial Services Mnemo Therapeutics SAS is a French biotechnology company that develops cell therapies to create accessible cures for cancer patients. The company is based in Paris, FR, and has subsidiaries in the United States. The company applies a novel approach to cell therapy using its enfinit platform, a groundbreaking drug discovery engine. Mnemo is committed to addressing the challenges in the field of immuno-oncology, such as a lack of cancer-specific targets, long-term persistence, and sensitivity. The company aims to engineer the future of immunotherapies to transform the lives of people with cancer by discovering novel cancer-specific targets and boosting immune activity to treat solid tumors. The company was founded in 2019 by Alain Maïore and Michel Sadelain. Robert LaCaze has been the CEO of the company since 2022. | Commercial Services |
- Borsa valori
- Insiders
- Sebastian Amigorena